[Translation] A Phase III, multicenter, randomized, double-blind, placebo-controlled study of vorasidenib (S095032/AG881) in Asian subjects with residual or recurrent grade 2 gliomas harboring IDH1 or IDH2 mutations
本研究的目的是在携带IDH1或IDH2突变的残留或复发性2级胶质瘤亚洲受试者中评估Vorasidenib的有效性、安全性和药代动力学(PK)特征。
[Translation] The aim of this study was to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of vorasidenib in Asian subjects with residual or recurrent grade 2 glioma harboring IDH1 or IDH2 mutations.